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ABSTRACT
Introduction: To examine changes in insulin
regimens and glycemic control during the
24 months after initiation of insulin in
patients with type 2 diabetes mellitus.
Methods: Data were collected over a 24-month
period from patients requiring insulin initiation as
part of usual care, in a prospective, observational
study. Changes in insulin regimens and
hemoglobin A1c (HbA1c) were examined within
countries (Germany, Greece, Spain) and overall.
Results: Prandial insulin only was most
commonly initiated in Germany, while basal
or premixed formulations were initiated in
Greece and Spain. In Germany, compared with
Greece or Spain, the patients were slightly
younger and had a shorter diabetes duration
when initiating insulin. For patients overall,
76.1% did not change their insulin regimen
between initiation and 24 months. The most
obvious change was a shift from prandial to
basal/bolus in Germany, with almost doubling
of mean daily insulin dose; in Greece and Spain,
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more patients stopped using insulin and the
trend to more complex regimens was not seen.
Overall, mean (SD) HbA1c decreased from
baseline (9.4 [1.7]%) to 6 months (7.2 [1.0]%),
but with little further change through
24 months (7.2 [1.1]%). HbA1c change with
basal/bolus insulin (-2.6 [2.0]%, baseline
10.1%) was greater than with basal only (-2.0
[1.8]%, baseline 9.3%). Mean HbA1c less than
7% was achieved and maintained over
24 months in Germany, but was not achieved
at any time in Greece or Spain.
Conclusions: Within 24 months of insulin
initiation, the majority of patients with type 2
diabetes remained on the same insulin regimen
initially instigated, despite the well-established
progressive loss of prandial and basal
endogenous insulin secretion. Adequate
glycemic control was best achieved where
insulin dosage adjustments and insulin
intensification took place.
Keywords: Basal/bolus insulin; Glycemic
control; Insulin therapy; Insulin regimen;
Prandial insulin; Type 2 diabetes
INTRODUCTION
Position statements from the American Diabetes
Association and the European Association for the
Study of Diabetes recommend an individual
target of hemoglobin A1c (HbA1c) [1–3]. The
targets and the management of glycemia should
be individualized and must be an integrated part
of overall care for each particular patient [1, 3, 4].
For patients with type 2 diabetes mellitus,
clinical guidelines generally propose a step-wise
progression of pharmacotherapy, with basal
insulin as the next step when lifestyle changes
and initial oral therapies have failed [1, 5].
Various consecutive insulin regimens have been
suggested, although with conflicting results
regarding the use of basal versus prandial
insulin [6, 7] and with little consensus
regarding the best options for intensification
[2–5, 8]. The UK Prospective Diabetes Study
(UKPDS) group reported that an initial decrease
in HbA1c was seen when patients started
insulin, but there was a continual increase
when followed long-term [9]. This is in
contrast to the Outcome Reduction with
Initial Glargine Intervention (ORIGIN) trial,
which showed that in early diabetes basal
insulin only could be a long-term option [10].
Therefore, it is unclear how alternative insulin
regimens perform under real-world conditions
in regard to glycemic control.
The INSulin TItration-GAining an
understanding of the burden of Type 2
diabetes in Europe (INSTIGATE) observational
study was designed to examine patients with
type 2 diabetes who initiated insulin as part of
their usual care [11]. Patients were initially
recruited in France, Germany, Greece, Spain,
and the UK, and results during the first
6 months have been reported [12]. Further
follow-up continued in Germany, Greece, and
Spain, and the present paper describes the
changing clinical outcomes during the
24-month follow-up period.
PATIENTS AND METHODS
Patient Population and Study Design
Patients were recruited at primary and secondary
care centres that routinely treated a large
number of patients with type 2 diabetes,
according to normal country-specific treatment
practices for insulin initiation. Investigators were
diabetologists, endocrinologists, and primary
care physicians who were either directly
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responsible for initiating insulin therapy or were
actively involved in further routine management
of patients who had initiated insulin therapy.
The study was noninterventional and, therefore,
all treatment decisions were made by the
physicians in consultation with the patients as
part of usual care. For each country, local
requirements for ethical review, informed
consent, and other regulatory approvals for an
observational study were met.
Patient characteristics, therapy prior to
insulin initiation, and differences between
participating countries were described
previously [11]. Patients had contact with their
physicians within the normal course of therapy,
and information was collected at baseline and
approximately 3, 6, 12, 18, and 24 months after
insulin initiation. For each patient throughout
the study, insulin regimens and use of oral
antidiabetic drugs (OADs) were recorded. HbA1c
and fasting blood glucose concentrations were
measured at local laboratories using standard
methods. Self-reported episodes of hypoglycemia
were recorded retrospectively at each visit.
Statistical Analysis
Demographic characteristics, treatment status,
and HbA1c concentrations were assessed using
descriptive summary statistics, with mean, SD,
median, minimum, maximum, and quartiles
calculated for continuous variables. Depending
on skewing of the data, either mean and SD or
medianandquartileswereused fordescription.For
categorical variables, absolute number of patients
and percentages based on total number of patients
per country and overall were calculated.
RESULTS
A total of 564 patients, out of 726 taking part in
the initial 6-month part of the INSTIGATE
study, were followed for up to 24 months in
Germany (155/256 patients; 60.5%), Greece
(237/263; 90.1%), and Spain (172/207; 83.1%).
The characteristics at the time of insulin
initiation of these patients, as well as of those
only participating in the initial 6-month part of
the study, are summarized in Table 1. Patients
starting insulin were, on average, younger and
with a shorter duration of diabetes in Germany
compared with Greece or Spain, although
HbA1c and fasting glucose concentrations were
similar.
Insulin regimens being used at baseline, 12,
and 24 months after insulin initiation are
summarized in Table 2. Prandial insulin only
was initially used by a large proportion of
patients in Germany (46.5%) and this
decreased by 12 months (30.1%), with a
concomitant increase in use of a basal/bolus
regimen. In Greece and Spain, basal insulin
only or premixed formulations were used by
most patients and there were only small
changes from baseline up to 24 months. Of
the 498 patients overall with data at
24 months, 379 (76.1%) did not change their
regimen between initiation and 24 months. Of
the patients who did change, 16 on basal only
and 16 on prandial only at baseline shifted to a
basal/bolus regimen. During the observation
period of 24 months, 48 patients (9.6%)
stopped the insulin treatment, the majority
of whom (27 patients) had started on basal
only.
Mean (SD) total daily insulin dose increased
in Germany from 0.28 (0.17) IU/kg at baseline
to 0.53 (0.34) IU/kg at 6 months, with little
further change up to 24 months (0.59 [0.41] IU/
kg). Much smaller changes in mean daily
insulin dose were observed in Greece (baseline:
0.41 [0.20] and 24 months: 0.54 [0.25] IU/kg)
and Spain (baseline: 0.27 [0.15] and 24 months:
0.34 [0.18] IU/kg).
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Concomitant OADs were not used at the
time of insulin initiation by 60.0% of patients
in Germany, and this percentage did not
change during the 24 months of insulin use.
In Greece, no OAD use was reported by a similar
proportion of patients at baseline (57.0%), but
this decreased to 47.6% at 24 months, with a
concomitant increase in the proportion taking
one OAD from 30.4% at baseline to 41.0% at
24 months. The respective percentages for no
OAD use for Spain were 40.1% at baseline and
27.0% at 24 months, with increases in the
proportion taking one (baseline 40.1% to
24 months 48.7%) and two OADs (baseline
19.2% to 24 months 23.7%). OAD use
included a sulfonylurea for 18.6% and 18.5%
of patients in Greece at baseline and 24 months,
23.8% and 27.6%, respectively, in Spain, but
only 5.2% and 3.4% in Germany.
Overall mean (SD) HbA1c (Fig. 1) decreased
from baseline (9.4 [1.7]%) to 6 months (7.2
[1.0]%), with little further change to 24 months
(7.2 [1.1]%). A mean HbA1c below 7% was
achieved and maintained only in Germany,
whereas in Spain a slight increase in mean
HbA1c was seen after the initial decrease at
6 months. The HbA1c and fasting glucose
changes from baseline to 24 months,
according to the insulin regimen being taken
at the 24-month time point, are shown in Fig. 2.
Mean HbA1c change observed with basal/bolus
regimens (-2.6 [2.0]%) was similar to premixed
regimens (-2.4 [1.6]%). Mean decreases in
HbA1c were lower for patients using only one
type of insulin (basal only: -2.0 [1.8]%,
prandial only: -2.2 [2.0]%). Changes in
fasting blood glucose concentrations according
to insulin regimen largely reflected the changes
Table 1 Baseline characteristics of patients in Germany,
Greece, and Spain who continued in the INSTIGATE
study for up to 24 months after initiation of insulin, and
for patients in these countries overall who continued or did
not continue beyond 6 months in the study
Overall (N5 726) Patients continuing the study






Number of patients 162 564 155 237 172
Completed 24-month
period (n, %)
– 498 (88.3) 119 (76.8) 227 (95.8) 152 (88.4)
Age (years) 63.6 (13.5) 64.3 (11.4) 61.0 (12.1) 66.0 (9.9) 64.9 (12.0)
Gender, male/female (%) 56.6/43.4 54.4/45.6 56.1/43.9 52.3/47.7 55.8/44.2
Time since diagnosis (years) 7.8 (8.0) 10.1 (7.2) 6.5 (6.2) 11.8 (7.0) 10.9 (7.1)
BMI (kg/m2) 29.6 (6.2) 29.3 (5.4) 30.6 (5.9) 28.2 (4.7) 29.6 (5.7)
HbA1c (%) 9.3 (2.0) 9.4 (1.7) 9.2 (2.0) 9.7 (1.6) 9.2 (1.5)
Fasting glucose (mmol/L) 11.9 (4.8) 12.2 (4.0) 11.7 (4.7) 12.8 (3.9) 11.9 (3.5)
Values are mean (SD), except for patients completing 24 months and gender which are percentages of patients; mean (SD)
are based on the number of patients with non-missing values and percentages are based on the total number of patients
BMI body mass index, HbA1c hemoglobin A1c, INSTIGATE INSulin TItration-GAining an understanding of the burden of
Type 2 diabetes in Europe
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in HbA1c concentration. At insulin initiation,
blood glucose monitoring was performed by
87% of patients, which increased to 98% at
12 months and 99% at 24 months, with no big
differences between countries.
There was a small increase in mean (SD) body
mass index (BMI) from 29.3 (5.4) kg/m2 at
baseline to 29.9 (5.6) kg/m2 at 12 months and
30.1 (5.3) kg/m2 at 24 months, with no obvious
differences between countries.
At least one episode of hypoglycemia (Fig. 3)
was reported by 5.0% of patients overall at
baseline for the prior 3 months; assessments at
each 6-monthly interval during the study
indicated an increase to 24.5% at 6 months,
and 15.3%, 16.6%, and 15.5% at the following
visits (12, 18, and 24 months, respectively). The
hypoglycemia incidence at 24 months was
higher in Greece (23.3%) than Germany
(10.1%) or Spain (7.9%). Throughout the
study, seven patients reported hypoglycemia
requiring hospitalization and confirmed by
glucose readings, which included two prior to
insulin initiation.
DISCUSSION
The present report of the INSTIGATE
observational study assessed data from up to
24 months of follow-up for patients who
initiated insulin in Germany, Greece, and
Spain. Most guidelines/position statements
recommend the initial use of basal insulin,
with subsequent addition of prandial insulin
when HbA1c levels remain elevated [1–5]. In the
present study, a majority of patients in
Germany started on prandial insulin only,
whereas most patients in Greece and Spain
started on basal insulin only or premixed
formulations. The difference in initial
treatment patterns may reflect the fact that all
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diabetologists [11] and may have adopted a
different approach, based on different national
guidelines [13]. Overall, changes in insulin
regimens over the 24-month study were small,
and 76% of patients did not change their
insulin regimen from that initiated.
In Germany, mean HbA1c concentration was
maintained below 7% from 6 months onwards.
This could be due to the predominant use of
multiple injections in Germany, starting with a
prandial approach and intensification to basal/
bolus insulin, with increasing overall insulin
dosage at 12 and 24 months. The maintenance
of HbA1c below 7% was consistent with the
previously reported German study using a basal/
bolus regimen [14]. In Greece, a slow decline in
mean HbA1c was seen, almost reaching target
levels at 24 months. An increase in use of a
basal/bolus regimen at 12 and 24 months and a
clinically relevant increase in insulin dosage
could be seen, as well as an increase in the
proportion of patients using concomitant
OADs. However, 21 patients in Greece stopped
using insulin altogether. In Spain, the lowest
mean HbA1c was achieved at 6 months with a
rise to above 7.5% after 24 months. This
outcome might be expected given the
progressive pathophysiology of type 2 diabetes
and the fact that there was little change in
treatment regimens and insulin dosage in
Spain, with the majority of patients remaining
on basal insulin only.
The authors would suggest that the greater
improvement in glycemic control seen in
Germany is most likely due to the insulin
intensification, with more complex regimens
and higher insulin dosage. Limitations of this
interpretation were that the patient cohorts
Fig. 1 Mean HbA1c concentration at each time-point from insulin initiation to 24 months for patients in each country
and for all patients combined. HbA1c hemoglobin A1c
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Fig. 2 Change in HbA1c and FBG from baseline to
24 months according to the insulin regimen being used at
the 24-month time point. Values shown are mean with SD
and simpliﬁed box plots (lower quartile, median, upper
quartile); number of patients are for patients on speciﬁed
insulin regimen with data at 24 months; values for an
additional 10 patients with other unspeciﬁed insulin
regimens are not shown. FBG fasting blood glucose, HbA1c
hemoglobin A1c
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were not totally comparable between countries
(e.g., the German cohort was younger and had a
shorter duration of diabetes), the study was only
observational and, therefore, no randomization
or standardization of the treatment took place.
In addition, the authors observed only a limited
number of patients and not all were willing to
continue for 24 month, which may have caused
a selection bias.
The present results were consistent with
those from the Treating To Target in Type 2
diabetes (4-T) study, where mean HbA1c was
significantly lower in patients treated with
premixed and/or prandial insulin, compared
with basal insulin, at 1 year [6]; after 3 years,
treatment intensification took place in about
70% of the patients, regardless of the initial
therapy regimen, highlighting the need for
further adjustment of therapy [15].
Furthermore, in a meta-analysis of data from
4,379 patients identified in 22 randomized
controlled trials up to October 2008, HbA1c
reductions were significantly greater with
biphasic and prandial insulin than with basal
insulin alone [16].
Consistent with the 6-month INSTIGATE
results [12], the rate of hypoglycemia was
lower in Germany at 12, 18, and 24 months,
despite the more intensive regimens and lower
HbA1c, compared with Greece where basal and
premixed regimens were more widely used. This
was in contrast to studies of patients treated
with prandial insulin who had improved post-
prandial glucose and HbA1c, but higher rates of
hypoglycemia compared with patients treated
with basal insulin alone [6, 17]. In a study by
Bretzel et al. (A Parallel design comparing an
OAD combination therapy with either Lantus
once daily or Lispro at mealtime in Type 2
Diabetic patients failing oral treatment
Fig. 3 Proportion of patients reporting at least one
episode of hypoglycemia during each period throughout
the study. Bars show percentages of patients in the
6 months prior to each study visit, except for baseline
where the value is for the prior 3 months; percentages are
based on the total number of patients per visit, by country
and overall
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[APOLLO]), an overall incidence of
hypoglycemic events that was four times
higher with rapid-acting prandial insulin than
with basal insulin was shown [7, 18]. However,
it has been suggested that the use of
sulfonylureas in the prandial insulin group of
APOLLO might have contributed to the higher
rate of hypoglycemia [19]. While only 5% of
patients in Germany reported concomitant
sulfonylureas in the present study, the
proportion in Greece was over 18%, which
may relate to the higher incidence of
hypoglycemia in Greece. However, in Spain
approximately 25% reported concomitant
sulfonylurea use, but the percentage reporting
hypoglycemic episodes were generally lowest.
This might reflect the smaller HbA1c reduction,
the lowest insulin dosages, and the highest
percentage of patients who stopped insulin use.
CONCLUSION
The majority of patients did not change insulin
regimen from that initiated, indicating that
guidelines of adaptation to individual patient
needs are not sufficiently adhered to.
Therapeutic algorithms suggest that basal
insulin should be followed by a combination
of basal with preprandial insulin to control
postprandial glucose fluctuations [20]. The
present INSTIGATE results suggest that good
glycemic control was attained by the highest
percentage of patients when insulin was
initiated earlier after diabetes diagnosis and
with earlier intensification. This underlines the
importance of timely escalation of insulin
therapies as the pathophysiology of type 2
diabetes progresses. Insulin regimens
substituting both basal and prandial insulin
insufficiency in type 2 diabetes were shown to
be feasible and effective in routine clinical
practice.
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